8,811 to 8,820 of 11,636 Results
Tabular Data - 122.9 KB - 337 Variables, 67 Observations - UNF:6:jqe2N2oiEVuuNxiHYG+8AA==
Original dataset in SPSS |
Plain Text - 264.1 KB -
MD5: 732dcfaf07f9539930fd4c6dcc2e17fd
Plain text version of dataset |
MS Excel Spreadsheet - 135.4 KB -
MD5: 721e00937042c5030fe63d230987664a
Microsoft Excel version of dataset |
Tabular Data - 46.5 KB - 8 Variables, 364 Observations - UNF:6:GrLG+FURgsdlJ84vsb56sQ==
|
Plain Text - 41.3 KB -
MD5: b611acc89f3114abed781e767dd71cac
|
Tabular Data - 4.2 KB - 5 Variables, 73 Observations - UNF:6:bSfxPmflMTInT3Rjh2oWDg==
|
Plain Text - 3.9 KB -
MD5: 752f3dcac0800afedb74fd28bcae0c86
|
Adobe PDF - 1004.0 KB -
MD5: df3053f44ced6f62204186ebde98ab1e
|
Nov 15, 2019
Skjeldestad, Finn Egil, 2019, "Replication Data for: Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian women – a cohort study", https://doi.org/10.18710/TDJV8X, DataverseNO, V1, UNF:6:M7dRklbtWaDqpYHrG432PA== [fileUNF]
The dataset comprise the variables necessary to replicate the results published. Abstract: Within 2021, Norway intends to complete implementation of HPV DNA-based primary screening for cervical cancer for women 34-69 years, while continue cytology-based screening for women 25-33 years. Over the recent years, the incidence of cervical cancer has inc... |
Adobe PDF - 749.1 KB -
MD5: 730fecab1e9ba23367963928e08317bf
|
